Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.

ABSTRACT:

Aim

We aimed to assess the gout management during the COVID-19 pandemic.

Methods

We assessed medication use, healthcare utilization, gout-specific health-related quality of life (HRQoL) on the Gout Impact Scale (GIS), psychological distress using the patient health questionnaire-4 (PHQ-4), and resilience in people with self-reported physician-diagnosed gout during the COVID-19 pandemic in a cross-sectional Internet survey.

Results

Among the 122 survey respondents with physician-diagnosed gout, 82% were prescribed urate-lowering therapy (ULT) and 66% were taking ULT daily; mean age was 54.2 years [standard deviation (SD), 13.8], 65% were male, and 79% were White. More regular use of gout medication was reported during the COVID-19 pandemic: allopurinol, 44%; colchicine

SUBMITTER: Singh JA 

PROVIDER: S-EPMC7576903 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature